# Evolution of comorbidities in people living with HIV between 2004 and 2014: cross-sectional analyses from ANRS CO3 Aquitaine cohort

Fabrice Bonnet, F. Le Marec, Olivier Leleux, Y. Gerard, D. Neau, E. Lazaro, P. Duffau, O. Caubet, M. A. Vandenhende, P. Mercie, et al.

► To cite this version:

Fabrice Bonnet, F. Le Marec, Olivier Leleux, Y. Gerard, D. Neau, et al.. Evolution of comorbidities in people living with HIV between 2004 and 2014: cross-sectional analyses from ANRS CO3 Aquitaine cohort. BMC Infectious Diseases, 2020, 20 (1), pp.850. 10.1186/s12879-020-05593-4. hal-03166652

HAL Id: hal-03166652

https://hal.science/hal-03166652

Submitted on 11 Mar 2021

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
RESEARCH ARTICLE

Open Access

<figure><img src="image_2.png" /></figure>

Check for
updates

# Evolution of comorbidities in people living with HIV between 2004 and 2014: cross-sectional analyses from ANRS CO3 Aquitaine cohort

F. Bonnet<sup>1,2,3*</sup>, F. Le Marec<sup>3</sup>, O. Leleux<sup>3</sup>, Y. Gerard<sup>2,4</sup>, D. Neau<sup>2,5</sup>, E. Lazaro<sup>1,2</sup>, P. Duffau<sup>1,2</sup>, O. Caubet<sup>2,6</sup>, M. A. Vandenhende<sup>1,2,3</sup>, P. Mercie<sup>1,2,3</sup>, C. Cazanave<sup>2,5</sup> and F. Dabis<sup>2,3</sup>

**Abstract**

**Background:** The objective of the study was to describe the evolution of chronic non-AIDS related diseases and their risk factors, in patients living with HIV (PLHIV) in the French ANRS CO3 Aquitaine prospective cohort, observed both in 2004 and in 2014 in order to improve long-term healthcare management.

**Methods:** The ANRS CO3 Aquitaine cohort prospectively collects epidemiological, clinical, biological and therapeutic data on PLHIV in the French Aquitaine region. Two cross sectional analyses were performed in 2004 and 2014, to investigate the patient characteristics, HIV RNA, CD4 counts and prevalence of some common comorbidities and treatment.

**Results:** 2138 PLHIV (71% male, median age 52.2 years in 2014) were identified for inclusion in the study, including participants who were registered in the cohort with at least one hospital visit recorded in both 2004 and 2014. Significant increases in the prevalence of diagnosed chronic kidney disease (CKD), bone fractures, cardiovascular events (CVE), hypertension, diabetes and dyslipidaemia, as well as an increase in treatment or prevention for these conditions (statins, clopidogrel, aspirin) were observed. It was also reflected in the increase in the proportion of patients in the “high” or “very high” risk groups of the disease risk scores for CKD, CVE and bone fracture score.

**Conclusions:** Between 2004 and 2014, the aging PLHIV population identified in the French ANRS CO3 Aquitaine prospective cohort experienced an overall higher prevalence of non-HIV related comorbidities, including CKD and CVD. Long-term healthcare management and long-term health outcomes could be improved for PLHIV by: careful HIV management according to current recommendations with optimal selection of antiretrovirals, and early management of comorbidities through recommended lifestyle improvements and preventative measures.

**Keywords:** HIV, Aging, Comorbidities, Cardiovascular events, Chronic kidney disease

<footnote>* Correspondence: fabrice.bonnet@chu-bordeaux.fr
Presented in part at the International Congress of Drug Therapy in HIV Infection, 23-26 October 2016, Glasgow, UK and the 8th edition of HIV Complications and Comorbidities Congress, 20-21 September 2018, Biarritz, France.</footnote>

<footnote n="1">¹CHU de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint-André, 1 rue Jean Burguet, 33000 Bordeaux, France</footnote>

<footnote n="2">²CHU de Bordeaux, COREVIH AQUITAINE, 33000 Bordeaux, France
Full list of author information is available at the end of the article</footnote>
## Background

Life expectancy of people living with HIV (PLHIV) has increased in the last two decades, due to improvements in patient care, including highly effective antiretroviral therapy (ART), HIV RNA suppression and CD4 cell count recovery [1, 2]. However, some analyses have shown that life expectancy in PLHIV remains lower compared to the general population. These differences, while they are more pronounced in lower income countries, are present across diverse settings (low and high income) ranging from 60% of HIV-negative life expectancy in Rwanda, to 90% in Canada [3].

Many factors have been associated with mortality, and observed decreases in life-expectancy, among PLHIV. Globally, there is evidence that women have a decreased life expectancy compared to men [3]. In Switzerland, differences in mortality were associated with educational attainment; life expectancy for PLHIV, 20 years or older, was 52.7 years (95% CI 46.4–60.1) for those with only compulsory education (16 years-old), compared to 60.0 years (95% CI 53.4–67.8) for those with higher education. Male gender, smoking, injection drug use, and low CD4 cell counts at enrolment were also independently associated with mortality in PLHIV [4].

At the same time, as the rate of mortality in PLHIV continues to decrease, the causes of death have shifted from AIDS to non-AIDS related causes, including cancers, complications of hepatitis coinfections, cardiovascular diseases, and non-AIDS infections [5]. Compared to the general population, PLHIV are more likely to develop comorbidities due to increasing age, higher exposure to risk factors, comorbidity risk associated with certain ARTs, and HIV related factors. Understanding these comorbidities is important to improve long-term healthcare management of PLHIV. The observational hospital-based prospective cohorts provide a useful tool for examining factors and long-term health outcomes within this population [6–8]. Evidence generated from these analyses could be important for policy-makers to project and plan for future needs for areas of care and associated costs [9, 10].

The objective of the present study was to describe the prevalence of chronic non-AIDS related diseases and their risk factors in aging patients included in the French ANRS CO3 Aquitaine prospective cohort, observed ten years apart (2004 and 2014).

## Methods

In the ANRS CO3 Aquitaine Cohort, HIV-1 infected patients in nine public hospitals of the Aquitaine region in Southwestern France, were followed prospectively since 1987. Details of the cohort have been described in detail previously [10]. The ANRS CO3 Aquitaine Cohort was approved by the French Commission Nationale de

L'informatique et des Libertés (CNIL). Participants provided written informed consent and the study adhered to the principles of Declaration of Helsinki.

The inclusion criterion for this analysis was ≥1 hospital visit in both calendar years, 2004 and 2014. Two descriptive, cross sectional analyses were performed at the beginning (2004) and at the end (2014) of the follow-up period. During each cross-sectional period, data were collected on patient characteristics, HIV markers, prevalence of comorbidities (at least once during follow up) and treatment recorded in that year (ART and comorbidity related medication). The ANRS CO3 Aquitaine cohort prospectively collects epidemiological, clinical, biological and therapeutic data on PLHIV in the French Aquitaine region. It also records clinical events and comorbidities through a simplified version of the International Classification of Diseases 10th Revision (ICD-10). The comorbidities recorded in the present analysis were selected as the most common non HIV-related comorbidities in aging populations and were the following: cardiovascular events (CVE) (myocardial infarction, invasive coronary procedure or stroke); chronic kidney disease (CKD) (defined as eGFR< 60 mL/min/ 1.73 m² for ≥3 months or recorded presence of an ICD-10 diagnosis code, by the physician in charge of the patient); acute kidney disease (AKD) (diagnosis of AKD (ICD-10)); bone fractures (any location; not differentiated according to high or low energy); hypertension (systemic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg or taking antihypertensive drugs without history of cardiovascular event); dyslipidaemia (elevated total cholesterol ≥6.2 mmol/l (240 mg/dL), and/or elevated LDL-cholesterol ≥4.1 mmol/L (160 mg/dL) and/or decreased HDL-cholesterol ≤0.9 mmol/L (35 mg/dL), and/or elevated triglycerides ≥2.3 mmol/L (200 mg/dL); diabetes (diagnosis of diabetes (at least one event within ICD-10 codes), or two consecutive blood glucose results fasting or random) ≥ 7 mmol/L or taking antidiabetic drugs or insulin); obesity (Body Mass Index (BMI) ≥30 kg/m²); depression (diagnosis (ICD-10) or receiving specific therapy); hepatitis B virus infection (at least one HbsAg+); hepatitis C virus infection (at least one anti-HCV+ or RNA+); and cancer (non-AIDS related). FRAX (Fracture Risk Assessment) score [11], D: A: D coronary risk score [12], and D:A:D renal risk score [13] were calculated to estimate the risk of fracture, cardiovascular disease and renal disease, respectively. All comorbidity data were assessed for both time points (2004 and 2014).

To detect differences between 2004 and 2014, t-tests were used on paired quantitative data (or the nonparametric alternative - Wilcoxon test); for paired qualitative data, McNemar's test or extended McNemar's tests were used (or the nonparametric alternative - Exact
McNemar's test). For results, *p*-values < 0.05 were considered statistically significant. All analyses were performed with SAS 9.3 (SAS Institute, Cary, NC, USA).

## Results

In the cohort, 3289 PLHIV had at least one hospital visit registered in 2004 and 3880 in 2014;2138 PLHIV had a visit in both years and were included in this analysis.

Among the 1051 PLHIV patients seen in 2004 but not in 2014, 421 died, and 730 were lost to follow-up. Patients who died between 2004 and 2014 differed from included patients. Patients who died between 2004 and 2014 were older (mean age 48.1 vs 43.3), more likely to be male (79% vs 71%), injection drug users (37% vs 18%), with lower CD4 counts (mean 380/mm³ vs 496/mm³) and less likely to be virally suppressed (< 50 copies/mL: 42% vs 51%). Patients lost to follow-up were similar to the 2138 patients followed at two time points (data not shown). They were slightly younger and more likely to be virally suppressed (54% vs 49%).

Of the 2138 included patients, 71% were males. In 2014, 62.3% were ≥ 50 years compared to 20.3% in 2004 (Table 1), 72.0% of patients achieved CD4 counts ≥500/mm³ compared to 43.6% in 2004 (*p* < 0.0001) and 91.5% achieved viral suppression (< 50 copies/ml) vs 50.9% in 2004 (*p* < 0.0001) (Table 2), showing that HIV markers have markedly improved over time.

Most comorbidities were significantly more prevalent in 2014. Hypertension and dyslipidemia were highly prevalent in HIV patients, being present in 56.3 and 50.9% of patients in 2014, respectively. While the annual prevalence of dyslipidemia decreased from 68.7% in

2004 (to 50.9% in 2014, *p* < 0.0001), and the proportion of PLHIV with LDL-cholesterol above 4.1 mmol/l (160 mg/dl) decreased from 26.1% in 2004 to 21.5% in 2014 (*p* = 0.003), in contrast, hypertension (+ 37.5%; *p* < 0.0001) and CKD (+ 14.7%; *p* < 0.0001) increased significantly during the period.

The prevalence of diabetes more than doubled in 2014 compared to 2004 (18.5% vs 8.4%; *p* < 0.0001), while the proportion of patients with obesity increased from 3.6 to 7.0% (*p* < 0.0001). The percentage of patients with depression remained stable between the two periods (13.5 and 14.0%, *p* = 0.59) and the percentage of patients living with a history of non-AIDS cancer increased significantly from 2.2 to 9.4% (*p* < 0.0001). Current tobacco consumption remained relatively unchanged over time (44.0 and 43.3%; *p* = 0.55) (Fig. 1). Following a similar trend to the prevalence of the comorbidities, prescriptions for all concomitant medications evaluated increased significantly from 2004 to 2014 (*p* < 0.0001), except for antidepressant drugs. Blood pressure and lipid-lowering drugs showed the highest increase and were prescribed to 22.7 and 29.3% of the population analyzed in 2014, respectively. However, only 46.8% of patients with two consecutive SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg received anti-hypertensive drugs in 2014. And among the 639 patients receiving anti-hypertensive drugs, only 22.8% had their last blood pressure measured < 140/90 mmHg.

The use of statins increased from 9.2 to 24% (*p* < 0.0001) between the two periods. In 2014, patients were treated more frequently with drugs for renal conditions and prevention of cardiovascular diseases (aspirin and clopidogrel) 14.4% for renal and 10.6% (aspirin or clopidogrel) for prevention of cardiovascular diseases respectively (Table 3).

The prevalence of cardiovascular and central nervous system events was approximately four times higher in 2014. History of AKD was recorded in 12.9% of patients in 2014. Approximately 10% of patients had an intermediate or high FRAX score in 2014 compared to 2.4% in 2004 (*p* < 0.0001) – results are based on data from 1884 patients with available scores in both 2004 and 2014 (observations missing data: *n* = 254; Table 4).

The proportion of patients at high or very high risk of developing coronary heart disease (CHD) over the subsequent 5 years, as measured by the D:A:D risk score, more than doubled within the 10 years of follow-up (18.4 to 46.4%; *p* < 0.001) (Fig. 2). The proportion of patients with D: A: D renal high-risk score increased from less than 30% in 2004 to over 50% in 2014 (Fig. 3).

## Discussion

In this large well-established French cohort, a significant improvement in HIV markers was observed as PLHIV

<table><caption>**Table 1** Sociodemographic characteristics and risk factors, in 2004 and 2014</caption><thead><tr><th></th><th>2004</th><th>2014</th></tr></thead><tbody><tr><td></td><td>(n = 2138)</td><td>(n = 2138)</td></tr><tr><td>Male Gender, n (%)</td><td>1517 (71.0)</td><td></td></tr><tr><td>Age (years), median (IQR)</td><td>42.2 (37.7;48.1)</td><td>52.2 (47.6;58.1)</td></tr><tr><td>Age > 50 years, n (%)</td><td>434 (20.3)</td><td>1334 (62.3)</td></tr><tr><td>Scholarship level, n (%)</td><td></td><td></td></tr><tr><td>Primary and Secondary</td><td>28 (59.6)</td><td></td></tr><tr><td>University</td><td>18 (38.3)</td><td></td></tr><tr><td>Others</td><td>1 (2.1)</td><td></td></tr><tr><td>BMI, median (IQR)</td><td>22.3 (20.1;24.5)</td><td>23.1 (20.7;25.9)</td></tr><tr><td>HIV risk factors, n (%)</td><td></td><td></td></tr><tr><td>MSM</td><td>863 (40.4)</td><td></td></tr><tr><td>Heterosexual</td><td>701 (32.8)</td><td></td></tr><tr><td>History of IDU</td><td>394 (18.4)</td><td></td></tr><tr><td>Others</td><td>180 (8.4)</td><td></td></tr></tbody></table>

Legend: BMI body mass index, IQR inter-quartile range, MSM men who have sex with men
<table><caption>**Table 2** HIV infection and ART treatment characteristics, in 2004 and 2014</caption><thead><tr><th></th><th>2004<br>n = 2138</th><th>2014<br>n = 2138</th><th>p-value</th></tr></thead><tbody><tr><td>Time since HIV diagnosis (years), mean (SD)</td><td>10.5 (5.5)</td><td>20.5 (5.5)*</td><td>&lt; 0.0001</td></tr><tr><td>CD4 count (cells/mm³), median (IQR)</td><td>457 (321;634)</td><td>647 (479;858)</td><td>&lt; 0.0001</td></tr><tr><td>CD4 count, strata, n (%)</td><td></td><td></td><td>&lt; 0.0001</td></tr><tr><td>≥ 500</td><td>879 (43.6)</td><td>1451 (72.0)</td><td></td></tr><tr><td>351–500</td><td>546 (27.1)</td><td>336 (16.7)</td><td></td></tr><tr><td>&lt; 350</td><td>590 (29.3)</td><td>228 (11.3)</td><td></td></tr><tr><td>Patients with viral suppression (&lt; 50 copies/ml), n (%)</td><td>1021 (50.9)</td><td>1835 (91.5)</td><td>&lt; 0.0001</td></tr><tr><td>Naive to ART, n (%)</td><td>213 (10.0)</td><td>14 (0.7)</td><td>&lt; 0.0001</td></tr><tr><td>Duration of ART (months), mean (SD)</td><td>77 (39)</td><td>190 (46)*</td><td>&lt; 0.0001</td></tr><tr><td>Current ART drug class, n (%)</td><td></td><td></td><td>&lt; 0.0001</td></tr><tr><td>2 NRTIs + 1 PI/r</td><td>505 (23.6)</td><td>693 (32.4)</td><td></td></tr><tr><td>2 NRTIs + 1 NNRTI</td><td>467 (21.8)</td><td>690 (32.3)</td><td></td></tr><tr><td>2 NRTIs + II</td><td>0 (0.0)</td><td>138 (6.5)</td><td></td></tr><tr><td>Other regimens</td><td>751 (35.1)</td><td>559 (26.1)</td><td></td></tr><tr><td>No treatment</td><td>415 (19.4)</td><td>58 (2.7)</td><td></td></tr><tr><td>AIDS stage, n (%)</td><td>442 (20.7)</td><td>525 (24.6)*</td><td>&lt; 0.0001</td></tr></tbody></table>

Legend: *AIDS acquired immunodeficiency syndrome, ART antiretroviral therapy, IQR inter-quartile range, NNRTI Non-Nucleoside Reverse Transcriptase Inhibitors, NRTI Nucleoside Reverse Transcriptase Inhibitors, PI/r ritonavir-boosted protease inhibitor, SD standard-deviation

*Cumulative data between 2004 and 2014

aged between 2004 and 2014 - consistent with findings from prior studies. In 2014, estimates from France have shown that 84% of PLHIV have been diagnosed [14]; in Aquitaine, we estimate that approximately 90% (data not published) of PLHIV have been diagnosed and more than 95% of them are included in the ANRS CO3 Aquitaine cohort; 97.3% of the patients were treated with antiretrovirals and 91.5% had a viral load below 50 copies/mL (and only 3.4% above 1000 copies/mL), suggesting that the 90–90–90 ONUSIDA goal was within reach. Only one quarter of patients had CD4 counts that remained below 500 CD4/mm³ in 2014 and this proportion decreased over time. The median age of participants

was 52.2 years in 2014 with 20.0% of patient being older than 60 years.

Despite the overall improvement in HIV markers over the ten-year period of this study, we also found a marked increase in the prevalence of comorbidities, risk factors associated with, and prescription of medicines to treat or to prevent, these conditions over the same period. Of the comorbidities observed, hypertension showed a particularly significant increase increasing from 18.8% in 2004 to, reaching 56.3% in 2014. These findings are similar to that in a sample comparing 540 PLHIV (median age: 52 years) to uninfected individuals from the AGEhIV Cohort study, which found the

<figure><img src="image_3.png" /></figure>
<table><caption>**Table 3** Prescription of comorbidity related medication, in 2004 and 2014</caption><thead><tr><th></th><th>2004 (n = 2138)</th><th>2014 (n = 2138)</th><th>p-value</th></tr></thead><tbody><tr><td>Antidiabetics, n (%)</td><td>51 (2.4)</td><td>125 (5.8)</td><td>&lt; 0.0001</td></tr><tr><td>Blood-pressure lowering treatment, n (%)</td><td>128 (6.0)</td><td>486 (22.7)</td><td>&lt; 0.0001</td></tr><tr><td>Lipid-lowering treatment, n (%)</td><td>331 (15.5)</td><td>626 (29.3)</td><td>&lt; 0.0001</td></tr><tr><td>Medication related to a risk of CV disease, n (%)</td><td></td><td></td><td></td></tr><tr><td>Aspirin</td><td>19 (0.9)</td><td>170 (8.0)</td><td>&lt; 0.0001</td></tr><tr><td>Clopidogrel</td><td>18 (0.8)</td><td>87 (4.1)</td><td>&lt; 0.0001</td></tr><tr><td>Treatment associated with renal conditions, n (%)</td><td>51 (2.4)</td><td>308 (14.4)</td><td>&lt; 0.0001</td></tr><tr><td>Psychotropic drugs, %</td><td>31 (1.4)</td><td>85 (4.0)</td><td>&lt; 0.0001</td></tr><tr><td>Antidepressant drugs, %</td><td>197 (9.2)</td><td>215 (10.1)</td><td>0.2872</td></tr></tbody></table>

Legend: CV cardiovascular

prevalence of hypertension to be 45.4% in PLHIV vs 30.5% in general population [15]. In these two studies, hypertension was the chronic comorbidity with the highest prevalence, and was present in approximately half of the patients who were 50 years and older. Recently, the French Microbreak study showed that cerebral small vessel disease (CSVD), which is a major predictor of future vascular events, cognitive impairment, frailty, and poor survival, was 60% more prevalent in PLHIV compared to the general population [16]. Age and hypertension were the main risk factors for CSVD, suggesting a possible explanation for the increased rate of neurocognitive disorders in PLHIV. It is noteworthy that in the Aquitaine clinical cohort, despite clear recommendations

included in the French Guidelines from 2004, anti-hypertensive drugs were prescribed to only half of the patients with confirmed hypertension, and that among patients receiving treatment only 22.8% were adequately treated. These findings highlight that the therapeutic objectives of adequately treating blood pressure have likely not yet been achieved to prevent hypertension complications, including CSVD, in this population. Future studies should consider that optimal control of hypertension will prevent CSVD and cognitive disorders in PLHIV. In fact, previous studies have already identified that being on antihypertensive treatment was associated with a lower probability of developing cardiovascular risk [17].

<table><caption>**Table 4** Proportion of patients with cardiovascular, vascular central nervous system events, kidney disease and fractures, in 2004 and 2014</caption><thead><tr><th></th><th>2004 (n = 2138)</th><th>2014 (n = 2138)</th><th>p-value</th></tr></thead><tbody><tr><td>Number of patients with cardiac, peripheral or CNS events, n (%)</td><td></td><td></td><td>&lt; 0.0001</td></tr><tr><td>0</td><td>2067 (96.7)</td><td>1851 (86.6)</td><td></td></tr><tr><td>1-3</td><td>67 (3.1)</td><td>234 (10.9)</td><td></td></tr><tr><td>≥ 4</td><td>4 (0.2)</td><td>53 (2.5)</td><td></td></tr><tr><td>Patients with history of CV events, n (%)</td><td>49 (2.3)</td><td>179 (8.4)</td><td>&lt; 0.0001</td></tr><tr><td>Patients with history of CNS event, n (%)</td><td>27 (1.3)</td><td>79 (3.7)</td><td>&lt; 0.0001</td></tr><tr><td>Patients with history of peripheral vascular events n (%)</td><td>10 (0.5)</td><td>127 (5.9)</td><td>&lt; 0.0001</td></tr><tr><td>Chronic Kidney Disease, n (%)</td><td></td><td></td><td></td></tr><tr><td>eGFR &lt; 60</td><td>133 (7.0)</td><td>230 (12.1)</td><td></td></tr><tr><td>Missing data*</td><td>237</td><td>237</td><td></td></tr><tr><td>Acute kidney disease (history)</td><td>41 (1.9)</td><td>275 (12.9)</td><td>&lt; 0.0001</td></tr><tr><td>FRAX score risk level, n (%)</td><td></td><td></td><td>&lt; 0.0001</td></tr><tr><td>Low (&lt; 5%)</td><td>1839 (97.6)</td><td>1701 (90.3)</td><td></td></tr><tr><td>Intermediate (5-7.5%)</td><td>39 (2.1)</td><td>129 (6.8)</td><td></td></tr><tr><td>High (&gt; 7.5%)</td><td>6 (0.3)</td><td>54 (2.9)</td><td></td></tr><tr><td>Missing data*</td><td>254</td><td>254</td><td></td></tr></tbody></table>

Legend: CV cardiovascular, CNS Central Nervous System (including stroke and hemorrhage):FRAX, Fracture Risk Assessment

*Patients with missing data were not considered and results were based on the total of the remaining patients who had no missing data
<figure><img src="image_4.png" /><figcaption>**Fig. 2** Distribution of patients by 5-year D:A:D Coronary Heart Risk Score, in 2004 and 2014</figcaption></figure>

The prevalence of dyslipidaemia, although decreasing between 2004 and 2014, remained at very high levels. The proportion of patients with LDL-cholesterol > 4.1 mmol/L decreased between 2004 and 2014 from 26.1 to 21.5%, possibly due to better management of dyslipidaemia, a switch of antiretrovirals (less use of boosted PIs and efavirenz) and a larger use of lipid lowering treatment (from 15.5 to 29.3% of patients; *p* < 0.0001), particularly statins.

With a prevalence of diabetes that more than doubled between 2004 and 2014 (18.5% in 2014) and a high stable prevalence of active smokers over those 10 years (43.3% in 2014), these results may explain largely the high increase of CVE between 2004 and 2014 in this cohort (14%). The prevalence of myocardial infarction and stroke was more than three times higher in 2014 than in 2004, while the prevalence of peripheral arterial disease was 10 times higher for the same period. Recent cohort

studies have shown that despite higher cardiovascular disease (CVD) risk profiles for PLHIV, the incidence of CVE by age class decreased in the recent years reaching the incidence observed in the general population [18]. Once again, increased use of more lipid-friendly antiretrovirals, has increased the emphasis put on CVD risk reduction in this population. One possible explanation for these findings could be the emerging profile, in the modern ART era, of a successfully treated HIV patient. However, we have also noticed that even if 19.9% of patients were at very high risk of coronary events according to the D:A:D equation risk, only 8.0% of the total cohort were treated with aspirin, including patients in primary and secondary prevention. The prescription of statins and aspirin in PLHIV remains largely suboptimal, with less than 50% of patients requiring statins and ASA being adequately treated, based on the EACS 6:1 guideline, advising the prescription of statins for patients with

<figure><img src="image_5.png" /><figcaption>**Fig. 3** Distribution of patients by D:A:D Renal Risk Score strata, in 2004 and 2014</figcaption></figure>
CVD risk < 20% according to Framingham CHD risk stratification [19].

Tobacco cessation remains a challenge for PLHIV. Despite numerous preventive actions, the prevalence of active smokers decreased by only 0.7% between 2004 and 2014. In a US study, HIV-infected smokers aged 40 years lost > 6 years of life expectancy from smoking, possibly outweighing the loss from HIV infection itself [20]. HIV is independently associated with both smoking and not quitting smoking according to algorithm models [21]. New approaches are key necessities to improve smoking cessation levels among PLHIV [22].

CKD followed the same trend of cardiovascular comorbidities reaching 62.5% of people with creatinine clearance below 90 mL/min, including 12.1% below 60 mL/min. More than half of the patients had a high risk score of CKD according to the D:A:D renal risk score strata. Addressing risk factors such as hypertension and diabetes will continue to be of key importance in this population.

At last, the issue of depression remains of concern with a stable prevalence of approximately 14% in both 2004 and 2014. However, the prevalence of depression might be underestimated - in a sample of 400 patients evaluated for neurocognitive disorders using the CES-D depression scale, we found that 27,5% of patients had depressive symptoms in the period 2007–2009 [23].

Our study may have some limitations. Measures for blood pressure, lipids and glycaemia (fasting or not fasting) were not systematically reported and the level of abnormalities observed might be overestimated. However, we strongly believe that these conditions have remained largely unchanged between 2004 and 2014 and thus, the evolution between the two time points was probably not impacted by any overestimation. One of the criteria in capturing comorbidities, in particular hypertension, included patients taking antihypertensive drugs (ICE, β blockers). This approach could create bias in capturing the true number of patients with hypertension as these medications may be used for other indications besides hypertension. The Aquitaine Cohort collected hospital based information in the region and thus provided a good representation of PLHIV in France. However as this is limited to a specific geographical region of France, and data on socioeconomic status were not collected, the results might not be generalizable to populations with largely different profiles (e.g. dietary habits, socioeconomic status and alcohol consumption). Patients who have died before 2014 were not considered in this analysis. The aim of this approach was to ensure accurately capturing data for both time points for the purposes of comparison and patients without data for both time points were excluded regardless of the reason. Additionally, this study only included only PLHIV and did not include a control group for comparison. This is could potentially be explored in a

future study using a matched control cohort to compare PLHIV to healthy controls and explore how aging could differentially affect the evolution of non-HIV comorbidities in the two populations.

As the majority of PLHIV are now over the age of 50, with age associated increasing comorbidities, the optimal HIV treatment regimen could lead to an early and effective management of these comorbidities and to a continuous improvement of PLHIV health status and quality of life. This would aim to address the effects of aging including regular monitoring and screening of major comorbidities risk modification measures, according to current recommendations, and optimal selection of ART to reduce renal and CVD risks along with balancing HIV outcomes.

In this context, effective ART options that balance HIV outcomes with a lower long-term impact on CVD, bone and renal events, would positively impact patient care and treatment. Adequate control of risk factors associated with these comorbidities, and counselling on cessation of smoking along with aiming for other lifestyle improvements, would be highly beneficial for PLHIV.

## Aquitaine cohort (France) composition

**Coordination:** F. Bonnet, F. Dabis. Scientific committee: F. Bonnet, S. Bouchet, D. Breilh, G. Chêne, F. Dabis, M. Dupon, H. Fleury, V. Gaborieau, D. Lacoste, D. Malvy, P. Mercié, P. Morlat, D. Neau, I. Pellegrin, JL. Pellegrin, S. Reigadas, S. Tchamgoué.

**Epidemiology and Methodology:** G. Chêne, F. Dabis, C. Fagard, S. Lawson-Ayayi, L. Richert, R. Thiébaut, L. Wittkop.

**Infectious Diseases and Internal Medicine:** K. André, F. Bonnet, N. Bernard, L. Caunègre, C. Cazanave, I. Chossat, C. Courtault, FA. Dauchy, S. De Witte, D. Dondia, M. Dupon, P. Duffau, H. Dutronc, S. Farbos, I. Faure, M. Foissac, V. Gaborieau, Y. Gerard, C. Greib, M. Hessamfar-Joseph, Y. Imbert, D. Lacoste, P. Lataste, E. Lazaro, D. Malvy, J. Marie, M. Mechain, P. Mercié, E. Monlun, P. Morlat, D. Neau, A. Ochoa, JL. Pellegrin, M. Pillot-Debelleix, T. Pistone, I. Raymond, MC. Receveur, P. Rispal, L. Sorin, S. Tchamgoué, C. Valette, MA. Vandenhende, MO. Vareil, JF. Viallard, H. Wille, G. Wirth. Immunology: JF. Moreau, I. Pellegrin.

**Virology:** H. Fleury, ME. Lafon, S. Reigadas, P. Trimoulet.

**Pharmacology:** S. Bouchet, D. Breilh, F. Haramburu, G. Miremont-Salamé.

**Data collection, Project Management and Statistical Analyses:** MJ. Blaizeau, I. Crespel, M. Decoin, S. Delveaux, F. Diarra, C. D'Ivernois, C. Hanappier, D. Lacoste, S. Lawson-Ayayi, O. Leleux, F. Le Marec, E. Lenaud, J. Mourali, E. Pernot, A. Pougetoux, B. Uwamaliya-Nziyumvira, R. Nawabzad. IT department and eCRF development: V. Conte, G. Palmer, V. Sapparrart, D. Touchard.
**Abbreviations**

AKD: Acute kidney disease; ART: Antiretroviral therapy; BMI: Body mass index; CHD: Coronary heart disease; CKD: Chronic kidney disease; CSVD: Cerebral small vessel disease; FRAX: Fracture Risk Assessment; HCV: Cardiovascular events; HIV: Human Immunodeficiency Virus; PLHIV: Patients living with HIV

**Acknowledgements**

The study results were presented in part at the International Congress of Drug Therapy in HIV Infection, 23-26 October 2016, Glasgow, UK and the 8th edition of HIV, Complications and Comorbidities Congress, 20-21 September 2018, Biarritz, France.

**Authors' contributions**

FB, OL, FD designed the study. FB, YG DN, EL, PD, OC, MAV, PM, CC collected the data and interpreted the results of the analysis. FLM and OL perform the management and the analysis of the data. All authors' have read and approved the manuscript.

**Funding**

The sources of support of this work include France Recherche Nord & Sud Sida-HIV Hépatites (ANRS) within the Coordinated Action no. 7 (AC7), the Bordeaux University Hospital through the COREVIH Aquitaine, Inserm (U1219), the Bordeaux School of Public Health (ISPED) and GILEAD. The sources of the support had no role in the design of the study and collection, analysis, interpretation of data and in writing the manuscript.

**Availability of data and materials**

All data generated or analysed during this study are included in this published article [and its supplementary information files].

**Ethics approval and consent to participate**

Participants provided written informed consent and the study is conducted in compliance with the Helsinki Declaration.

**Consent for publication**

Yes

**Competing interests**

Dr. Bonnet reports non-financial support from Gilead, Janssen, Viiv health-care, and MSD, personal fees from Gilead, Janssen, Viiv healthcare, and MSD, outside the submitted work; Dr. Cazanave reports personal fees and non-financial support from Gilead, Viiv Healthcare, and MSD, outside the submitted work; All other authors report nothing to disclose.

**Author details**

¹CHU de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint-André, 1 rue Jean Burguet, 33000 Bordeaux, France. ²CHU de Bordeaux, COREVIH AQUITAINE, 33000 Bordeaux, France. ³Université de Bordeaux, INSERM U1219, ISPED, 33000 Bordeaux, France. ⁴CH de Dax, Service de Maladies Infectieuses, 40100 Dax, France. ⁵CHU de Bordeaux, Service des maladies Infectieuses et Tropicales, 33000 Bordeaux, France. ⁶CH de Libourne, Service de Maladies Infectieuses, 33500 Libourne, France.

Received: 13 August 2019 Accepted: 5 November 2020

Published online: 16 November 2020

**References**

1. Nakagawa F, May M, Phillips A. Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis. 2013;26:17-25.

2. The Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4:e349-56.

3. Wandeler G, Jonhson LF, Egger M. Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population. Curr Opin HIV/AIDS. 2016;11:492-500.

4. Gueler A, Moser A, Calmy A, et al. Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. AIDS. 2017;31: 427-36.

5. Goehringer F, Bonnet F, Salmon D, et al. Causes of death in HIV-infected individuals with Immunovirologic. Success in a National Prospective Survey. AIDS Res Hum Retrovir. 2017;33:187-93.

6. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011;53:1130-9.

7. Orlando G, Meraviglia P, Cordier L, et al. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med. 2006;7:549-57.

8. Luz PM, Bruyand M, Ribeiro S, et al. AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000-2008: hospital-based cohort studies. BMC Infect Dis. 2014;14:278.

9. Smit M, Cassidy R, Cozzi-Lepri A, et al. Quantifying the future clinical burden of an ageing HIV-positive population in Italy: a mathematical modelling study. International Congress of Drug Therapy in HIV Infection 2016, Glasgow. JIAS. 2016;19(suppl 7):120.

10. Thiebaut R, Morlat P, Jacqmin-Gadda H, et al. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidemiologie du SIDA en Aquitaine (GECSA) AIDS. 2000;14:971-8.

11. Brown TT, Hoy J, Borderi M, et al. Recommendations for evaluation and Management of Bone Disease in HIV. Clin Infect Dis. 2015;60:1242-51.

12. Friis-Møller N, Thiebaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehab. 2010;17:491-501.

13. Mocroft A, Lundgren JD, Ross M, et al. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the Dα:D study. PLoS Med. 2015;12:e1001809. https://doi.org/10. 1371/journal.pmed.1001809.

14. Gourlay A, Noori T, Pharris A, et al. The human immunodeficiency virus continuum of Care in European Union Countries in 2013: data and challenges. Clin Inf Dis. 2017;64:1644-56.

15. Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Inf Dis. 2014;59:1787-97.

16. Moulignier A, Savatovsky J, Godin O, et al. Cerebral small-vessel disease in HIV-infected patients well controlled on CART. 17th CROI, Seattle, Washington, 2017. Abstract 75.

17. Shahmanesh M, Schultze A, Burns F, et al. The cardiovascular risk management for people living with HIV in Europe: how well are we doing? AIDS. 2016;30:2505-18.

18. Klein DB, Leyden WA, Xu L, et al. Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care. Clin Infect Dis. 2015;60:1278-80.

19. De Socio GV, Ricci E, Parruti G, et al. Statins and aspirin use in HIV-infected people: gap between European AIDS clinical society guidelines and clinical practice: the results from HIV-HY study. Infection. 2016;44:589-97.

20. Reddy KP, Parker RA, Losina E, et al. Impact of cigarette smoking and smoking cessation on life expectancy among people with HIV: a US-based modeling study. J Infect Dis. 2016;214:1672-81.

21. Regan S, Meigs JB, Grinspoon SK, Triant VA. Determinants of smoking and quitting in HIV-infected individuals. PLoS One. 2016;11:e0153103.

22. Lifson AR, Neuhaus J, Arribas JR, et al. Smoking-related health risks among persons with HIV in the strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health. 2010;100:1896-903.

23. Bonnet F, Amieva H, Marquant F, et al. Cognitive disorders in HIV-infected patients: are they HIV-related? ANRS CO3 Aquitaine cohort, Bordeaux, France, 2007-2009. AIDS. 2013;27:391-400.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.